| A Phase Ⅲ Clinical Study of SNA02-48 Injection (NCT07633119) | Sinovac Life Sciences Co., Ltd. | 2026-06-28 |
| Clinical Trial of PCV13 in Infants Aged Approximately 2 Months (42 to 89 Days) (NCT07593924) | Sinovac Life Sciences Co., Ltd. | 2026-05-01 |
| Phase Ia Clinical Trial of Group ACYW135X Meningococcal Conjugate Vaccine (NCT07374510) | Sinovac Life Sciences Co., Ltd. | 2026-01-21 |
| Clinical Trial of PCV24 in Infants and Children Aged 2 Months to 5 Years (NCT07300644) | Sinovac Life Sciences Co., Ltd. | 2025-11-25 |
| Clinical Trial of PCV24 in Adults Aged ≥18 Years (NCT07543198) | Sinovac Life Sciences Co., Ltd. | 2025-06-18 |
| Clinical Trial of PCV24 in Infants Aged 2-23 Months (NCT06800261) | Sinovac Life Sciences Co., Ltd. | 2025-05-08 |
| Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SNA02-48 Injection in Chinese Adult Participants (NCT06939777) | Sinovac Life Sciences Co., Ltd. | 2025-04-28 |
| PhaseⅡClinical Trial of Oral Hexavalent Reassortant Rotavirus Attenuated Live Vaccine (Vero Cells) (NCT06967272) | Sinovac Life Sciences Co., Ltd. | 2025-01-20 |
| Clinical Trial of 13-Valent Pneumococcal Conjugate Vaccine (NCT06617715) | Sinovac Life Sciences Co., Ltd. | 2024-10-23 |
| Clinical Trial of PCV24 in Children Aged 2-17 Years (NCT06550830) | Sinovac Life Sciences Co., Ltd. | 2024-09-07 |
| Clinical Trial of PCV24 in Adults (NCT06474377) | Sinovac Life Sciences Co., Ltd. | 2024-06-21 |
| The Oral Hexavalent Reassortant Rotavirus Attenuated Live Vaccine (Vero Cells) (NCT06950645) | Sinovac Life Sciences Co., Ltd. | 2024-03-27 |
| Safety and Immunogenicity of Tetanus Vaccine, Adsorbed in 18~44 Years Old Population (NCT06049940) | Sinovac Life Sciences Co., Ltd. | 2023-09-01 |
| SA55 Injection: a Potential Therapy for the Prevention and Treatment of COVID-19 (NCT06050460) | Sinovac Life Sciences Co., Ltd. | 2023-06-15 |
| SA55 Novel Coronavirus Broad-spectrum Neutralizing Antibody Nasal Spray in Health People (NCT06048393) | Sinovac Life Sciences Co., Ltd. | 2023-05-31 |
| Safety and Immunogenicity Study of a 13-valent Pneumococcal Polysaccharide Conjugate Vaccine (NCT05092386) | Sinovac Life Sciences Co., Ltd. | 2023-01-03 |
| Efficacy and Safety of SA58 Nasal Spray in Close Contact With COVID-19 People (NCT05667714) | Sinovac Life Sciences Co., Ltd. | 2022-11-26 |
| Efficacy and Safety of Anti-COVID-19 Antibody SA58 Nasal Spray to Prevent Infection in High-risk Populations (NCT05664919) | Sinovac Life Sciences Co., Ltd. | 2022-10-30 |
| Immunogenicity，Safety and Cross - Immune Response With Mutant Strains of a Third Dose of an Inactivated COVID-19 Vaccine (NCT05329038) | Sinovac Life Sciences Co., Ltd. | 2022-04-19 |
| Immunogenicity and Safety of a Third Dose of COVID-19 Vaccine(Vero Cell), Inactivated in the Elderly (NCT05398926) | Sinovac Life Sciences Co., Ltd. | 2021-12-06 |
| Safety of an Inactivated SARS-CoV-2 Vaccine for Prevention of COVID-19 in Children and Adolescents (NCT04992208) | Sinovac Life Sciences Co., Ltd. | 2021-07-24 |
| Safety of an Inactivated SARS-CoV-2 Vaccine (CoronaVac) in Children and Adolescents (NCT04884685) | Sinovac Life Sciences Co., Ltd. | 2021-05-03 |